Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top generic entry drug savings in Canada by public drug plan 2012/2013

Savings for top 5 generic entry drugs in select Canadian drug plans in 2012/2013 (in 1,000 Canadian dollars)

by Statista Research Department, last edited Mar 31, 2015
Top generic entry drug savings in Canada by public drug plan 2012/2013 This statistic depicts the savings for the top five generic entry drugs in Canada in fiscal year 2012/2013, distributed by public drug plan. In that year, savings for Nabilone (Cesamet) in Alberta's public drug plan amounted to 719,000 Canadian dollars.
Show more

Savings for top 5 generic entry drugs in select Canadian drug plans in 2012/2013 (in 1,000 Canadian dollars)

Public drug planRosuvastatin (Crestor)Candesartan (Atacand)Nabilone (Cesamet)Entacapone (Comtan)Bosentan (Tracleer)
------
------
------
------
------
------
------
------
Public drug planRosuvastatin (Crestor)Candesartan (Atacand)Nabilone (Cesamet)Entacapone (Comtan)Bosentan (Tracleer)
------
------
------
------
------
------
------
------
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Statista Research Department, last edited Mar 31, 2015
This statistic depicts the savings for the top five generic entry drugs in Canada in fiscal year 2012/2013, distributed by public drug plan. In that year, savings for Nabilone (Cesamet) in Alberta's public drug plan amounted to 719,000 Canadian dollars.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.